Hyperfine, Inc. (Nasdaq: HYPR) reported preliminary, unaudited financial results for the third quarter ended September 30, 2026, in a Form 8-K filed on October 8, 2026. The company announced estimated total revenue of approximately $6.0 million for the quarter, representing a 53% sequential increase compared to the prior quarter.
For the nine months ended September 30, 2026, Hyperfine reported estimated total revenue of approximately $13.8 million. This figure reflects a 66% increase compared to the same period in the prior year. The company also disclosed preliminary unaudited cash and cash equivalents of approximately $37.9 million as of September 30, 2026.
In addition to revenue figures, the company provided preliminary estimates for net cash burn. For the third quarter of 2026, net cash burn, excluding financing proceeds, is expected to be approximately $5.6 million. This represents a 29% sequential improvement compared to the second quarter of 2026. Notably, preliminary unaudited third-quarter revenue is expected to exceed preliminary net cash burn for the first time.
Hyperfine reaffirmed its full-year 2026 financial guidance. The company continues to expect revenue for the full year to be approximately $20 million to $22 million, representing 55% growth at the midpoint compared to full year 2025. The company also expects full-year 2026 net cash burn, excluding financing proceeds, to be approximately $26 million to $28 million.
Management stated that the preliminary results demonstrate execution of the commercial strategy, noting momentum across health systems, hospital sites of care, and international markets. The company plans to provide complete third quarter 2026 financial results during its earnings call on November 9, 2026.
